Table 2

Genotype and allele frequencies of CYP2A13 and CYP2A6 among cases and controls, and their association with lung cancer

GenotypeControls (n = 791)All cases (n = 724)Cases with SCCa (n = 263)Cases with ACa (n = 319)Case with othera (n = 142)
n(%)n(%)n(%)n(%)n(%)
CYP2A13
CC 652(82.4)632(87.3)219(83.3)288(90.3)125(88.0)
CT 130(16.4)85(11.7)37(14.1)31(9.7)17(12.0)
TT 9(1.2)7(1.0)7(2.6)0(0.0)0(0.0)
T allele frequency0.090.070.100.040.06
Adjusted OR (95% CI)b0.62 (0.45–0.87)0.86 (0.57–1.29)0.41 (0.23–0.71)0.58 (0.32–1.09)
CYP2A6
*1/*1 680(86.0)630(87.0)235(89.4)276(86.5)119(83.8)
*1/*4 102(12.9)84(11.6)23(8.7)40(12.6)21(14.8)
*4/*4 9(1.1)10(1.4)5(1.9)3(0.9)2(1.4)
*4 allele frequency0.080.070.060.070.09
Adjusted OR (95% CI)b0.97 (0.72–1.31)0.76 (0.48–1.21)0.95 (0.65–1.40)1.21 (0.73–1.98)
  • a SCC, squamous cell carcinoma; AC, adenocarcinoma; other includes undifferentiated cancer (n = 60), bronchioalveolar carcinoma (n = 27), and small cell carcinoma (n = 55).

  • b ORs were calculated with the CYP2A13 CC or CYP2A6 *1/*1 genotype as the reference group and adjusted for age, sex, smoking status, or pack-years (<27 or ≥27). The CYP2A13 TT or CYP2A6 *4/*4 genotype was combined with the CT or *1/*4 genotype for the calculation.